Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER vs CALCIUM GLUCEPTATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium is the major intracellular cation. It is essential for the maintenance of intracellular tonicity, nerve impulse transmission, cardiac muscle contractility, and skeletal muscle contraction. Dextrose provides a source of calories and may help to correct hypoglycemia.
Calcium gluceptate is a calcium salt that dissociates to provide calcium ions, which are essential for various physiological processes including nerve conduction, muscle contraction, blood coagulation, and cardiac function. It acts as a calcium replenisher.
Replacement of potassium in patients with hypokalemia,Prevention of hypokalemia in patients who would be at risk from developing this condition,Source of calories and fluid in parenteral nutrition when potassium supplementation is required
Treatment of hypocalcemia,Calcium supplementation in patients requiring parenteral calcium,Treatment of hypermagnesemia,Cardiac resuscitation (as an adjunct),Treatment of calcium channel blocker overdose
Intravenous infusion at a rate not exceeding 10 m Eq/hour (0.75 m Eq/kg/hour). Typical dose: 20-40 m Eq potassium chloride in 1 liter D5W administered over 8-12 hours.
IV: 2-4 mg/kg elemental calcium (5-10 m L of 0.45 m Eq/m L solution) administered slowly over 10-20 minutes. May repeat if needed. Maximum dose: 20 m L per infusion.
Potassium has no true elimination half-life as it is an endogenous electrolyte; redistribution half-life is approximately 1–1.5 hours for exogenous loads, reflecting cellular uptake and renal excretion. In anephric patients, half-life extends to 12–24 hours due to reliance on gastrointestinal and dialysis excretion.
Terminal elimination half-life: 2-4 hours (normal renal function); prolonged to 12-24 hours in renal impairment.
Potassium is primarily excreted unchanged by the kidneys. Dextrose is metabolized via glycolysis and subsequent pathways to carbon dioxide and water, yielding energy.
Calcium gluceptate is not metabolized; it dissociates into calcium ions and gluceptate. Calcium ions are excreted primarily in feces and urine, with renal handling involving reabsorption and secretion.
Renal: >90% of potassium excreted by kidneys, with distal tubular secretion and reabsorption. Fecal: ~10% eliminated via gastrointestinal tract. Biliary: negligible.
Renal: >90% excreted unchanged in urine. Biliary/fecal: <5%.
~10% bound to plasma proteins (albumin). Unbound fraction is physiologically active.
~45% bound to albumin.
Total body potassium Vd ~0.5 L/kg (approximates lean body mass). For intravenously administered potassium: initial Vd approximates extracellular fluid (0.2 L/kg) with redistribution into cells over 15–30 minutes. Clinical meaning: Low Vd indicates rapid equilibration; loading doses must account for intracellular shift to avoid hyperkalemia.
0.15-0.25 L/kg; represents distribution mainly in extracellular fluid.
Intravenous: 100%. Oral: ~90% (absorbed in small intestine). No other routes relevant.
IV: 100%; IM: not well characterized; oral: negligible (absorbed poorly, systemic bioavailability <1% as calcium gluceptate dissociates in GI tract).
GFR >50 m L/min: No adjustment. GFR 30-50 m L/min: Reduce dose by 25-50%. GFR 10-30 m L/min: Reduce dose by 50-75%. GFR <10 m L/min: Avoid use or use with extreme caution; consider alternative.
GFR >50: No adjustment. GFR 30-50: Reduce dose by 25%. GFR <30: Reduce dose by 50% and monitor serum calcium closely. Dialysis: Dose after hemodialysis.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 25-50% due to risk of hyperkalemia. Child-Pugh C: Avoid use; alternative therapy recommended.
No dose adjustment required for hepatic impairment. However, monitor ionized calcium in severe hepatic failure due to altered binding proteins.
Neonates and infants: 0.5-1 m Eq/kg/dose IV, not to exceed 0.5 m Eq/kg/hour. Children: 1-3 m Eq/kg/day IV, maximum infusion rate 0.5-1 m Eq/kg/hour; maximum concentration 40 m Eq/L.
Neonates and infants: 100-200 mg elemental calcium/kg/day IV divided every 6 hours. Children: 200-500 mg elemental calcium/kg/day IV divided every 6 hours. Maximum: 1 g elemental calcium per dose.
Start at lower end of dosing range (e.g., 10-20 m Eq per liter) and titrate slowly. Monitor renal function and serum potassium frequently. Maximum infusion rate: 5-10 m Eq/hour.
Use lower initial doses (e.g., 1-2 mg/kg elemental calcium) due to reduced renal function and increased risk of hypercalcemia. Monitor serum calcium and phosphate levels.
Potassium chloride injections are for intravenous use only. Rapid infusion may cause hyperkalemia and cardiac arrest. Concentrated potassium chloride solutions (>=2 m Eq/m L) must be diluted before use. Do not administer undiluted.
No FDA black box warning.
Monitor serum potassium levels frequently to avoid hyperkalemia,Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia,Do not administer if solution is discolored or contains particulate matter,Check for compatibility with other medications in the same line
Risk of hypercalcemia, especially in patients with renal impairment,Avoid rapid intravenous administration to prevent cardiac arrest,Use with caution in patients with sarcoidosis or digitalis toxicity,Monitor serum calcium levels during therapy,Extravasation may cause tissue necrosis
Hyperkalemia,Severe renal impairment with oliguria or anuria,Conditions that cause potassium retention (e.g., Addison's disease, systemic acidosis),Hypersensitivity to potassium chloride or dextrose
Hypercalcemia,Hypersensitivity to calcium gluceptate or any component,Ventricular fibrillation,Patients with known calcium-containing calculi
Avoid excessive consumption of potassium-rich foods (e.g., bananas, oranges, potatoes, spinach, avocados) and salt substitutes containing potassium chloride. Limit high-sodium foods as they may affect fluid and electrolyte balance.
Avoid high-calcium foods (dairy, fortified cereals) during acute therapy to prevent hypercalcemia. Limit vitamin D-rich foods (fatty fish, fortified milk). Do not take oral calcium within 1 hour of iron or thyroid medications. Avoid excessive caffeine and alcohol.
Potassium chloride and dextrose are not teratogenic. There is no evidence of fetal harm from potassium chloride or dextrose at standard doses. Trimester-specific risks are not applicable.
Calcium gluceptate is a calcium salt used for calcium supplementation. No specific teratogenic effects are reported; calcium is essential for fetal development. First trimester: No increased risk of major malformations. Second and third trimesters: Adequate intake supports fetal skeletal mineralization; excess may cause hypercalcemia in the infant. No known teratogenicity.
Potassium chloride and dextrose are endogenous substances normally present in breast milk. No safety concerns at standard doses. M/P ratio not established; not clinically relevant as both are normal milk constituents.
Calcium gluceptate is considered safe during breastfeeding. Calcium is naturally present in breast milk; supplementation does not significantly alter milk calcium levels. M/P ratio not established, but endogenous calcium transport suggests minimal risk. Use with caution in mothers with hypercalcemia.
No specific dose adjustment required for pregnancy; however, monitor for fluid overload and electrolyte imbalances due to increased plasma volume and GFR in pregnancy; adjust rate based on serum potassium and glucose.
No specific dose adjustment required in pregnancy; maintain recommended daily intake (1000-1300 mg elemental calcium). Pharmacokinetic changes in pregnancy (increased absorption, renal clearance) may slightly alter requirements, but standard doses are safe. Intravenous use should be adjusted based on serum calcium monitoring.
Administer via central line if concentration exceeds 0.1% (20 m Eq/L) to avoid phlebitis. Do not exceed infusion rate of 10 m Eq/hour. Contraindicated in severe renal impairment (Cr Cl <30 m L/min), hyperkalemia, or Addison's disease. Monitor ECG for peaked T waves and serum potassium levels. Use with caution in patients on ACE inhibitors, ARBs, or potassium-sparing diuretics.
Calcium gluceptate is used for acute hypocalcemia, hyperkalemia cardiotoxicity, and hypermagnesemia. Administer IV slowly (0.5-1 m L/min) to avoid arrhythmias; monitor ECG during infusion. Do not mix with bicarbonate, phosphate, or sulfate-containing solutions. Extravasation causes tissue necrosis; use central line for peripheral therapy. Correct hypomagnesemia before calcium therapy to prevent refractory hypocalcemia.
Report any signs of hyperkalemia such as muscle weakness, palpitations, or tingling sensations.,Avoid potassium-containing salt substitutes or supplements unless approved by your doctor.,This solution contains dextrose; if you have diabetes, monitor blood glucose closely.,Inform your healthcare provider about all medications, especially heart or blood pressure medicines.,Do not stop or change the infusion rate on your own.
Report any burning or pain at injection site immediately.,Avoid taking calcium supplements or antacids without consulting your doctor.,Tell your doctor if you have kidney stones, parathyroid disorders, or heart disease.,Do not stop other calcium medications abruptly.,Seek emergency care for difficulty breathing or chest tightness after infusion.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER vs CALCIUM GLUCEPTATE, answered by our medical review team.
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER is a Electrolyte Supplement that works by Potassium is the major intracellular cation. It is essential for the maintenance of intracellular tonicity, nerve impulse transmission, cardiac muscle contractility, and skeletal muscle contraction. Dextrose provides a source of calories and may help to correct hypoglycemia.. CALCIUM GLUCEPTATE is a Electrolyte Supplement that works by Calcium gluceptate is a calcium salt that dissociates to provide calcium ions, which are essential for various physiological processes including nerve conduction, muscle contraction, blood coagulation, and cardiac function. It acts as a calcium replenisher.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER and CALCIUM GLUCEPTATE depend on the specific clinical indication. These are both Electrolyte Supplement agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion at a rate not exceeding 10 m Eq/hour (0.75 m Eq/kg/hour). Typical dose: 20-40 m Eq potassium chloride in 1 liter D5W administered over 8-12 hours.. The standard adult dose of CALCIUM GLUCEPTATE is: IV: 2-4 mg/kg elemental calcium (5-10 m L of 0.45 m Eq/m L solution) administered slowly over 10-20 minutes. May repeat if needed. Maximum dose: 20 m L per infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER and CALCIUM GLUCEPTATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Potassium chloride and dextrose are not teratogenic. There is no evidence of fetal harm from potassium chloride or dextrose at standard doses. Trimester-specific risks are not appl. CALCIUM GLUCEPTATE is classified as Category C. Calcium gluceptate is a calcium salt used for calcium supplementation. No specific teratogenic effects are reported; calcium is essential for fetal development. First trimester: No. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.